Business

Syngene Q3 PAT declines 44% to ₹73 cr on biologics client impact

The company’s revenue from operations was down by 3 per cent year-on-year at ₹917 crore.

Economist AdminEconomist Admin
Syngene Q3 PAT declines 44% to ₹73 cr on biologics client impact
The company’s revenue from operations was down by 3 per cent year-on-year at ₹917 crore.
Read More

Tags:

Previous Article

Storage in India’s key resevoirs drops to 71% of capacity

Next Article

Row erupts as Karnataka Governor skips paragraphs critical of Centre in Legislat...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Economist Admin
Economist Admin Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.

Related Posts

Hexaware launches ‘Zero license’ to replace traditional SaaS systems with Agentic AI in months

Hexaware launches ‘Zero license’ to replace traditional...

Economist Admin

SAT stays SEBI's 2-year market ban on Omaxe and its key executives

SAT stays SEBI's 2-year market ban on Omaxe and its key...

FEDA-HQ

‘Deepfakes spreading and more AI companions’: seven takeaways from the latest artificial intelligence safety report

‘Deepfakes spreading and more AI companions’: seven tak...

Economist Admin